-
Zenas BioPharma NasdaqGS:ZBIO Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Location: 852 Winter Street, Waltham, MA, 02451, United States | Website: https://zenasbio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
126.8M
Cash
312.4M
Avg Qtr Burn
-34.41M
Short % of Float
23.24%
Insider Ownership
21.20%
Institutional Own.
74.81%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Obexelimab (CD19xFcyRIIb) Details IgG4-related disease | Phase 3 Data readout | |
Obexelimab (CD19xFcyRIIb) Details Systemic lupus erythematosus | Phase 2 Data readout | |
Obexelimab (CD19xFcyRIIb) Details Multiple sclerosis | Phase 2 Data readout | |
Obexelimab (CD19xFcyRIIb) Details Warm autoimmune hemolytic anemia | Failed Discontinued |